BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
BioAge will host an R&D Day on May 8, 2026, to present Phase 1 data for its lead NLRP3 inhibitor BGE-102, targeting cardiovascular and retinal diseases. The event will feature presentations from four academic and clinical experts, including Board Member Dr. Michael Davidson, discussing the role of inflammation and the therapeutic rationale for BGE-102.
Key figures
- Drug Name
- BGE-102
- Phase Of Trial
- Phase 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.